DFDA

Isoniazid (INH) Monotherapy (9 months for Latent TB Infection)

Treatment for Drug Susceptible Tuberculosis

Typical Dosage: Isoniazid 300mg daily

Effectiveness
75%
Safety Score
65%
Clinical Trials
300
Participants
100K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Isoniazid 300mg daily
Time to Effect
Prevention initiated within weeks, protective effect over years
Treatment Duration
9 months
Evidence Quality
HIGH
Number Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$200
Side Effect Mgmt:$50
Total Annual:$325
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$30,000/QALY
QALYs Gained
0.1
Isoniazid (INH) Monotherapy (9 months for Latent TB Infection) Outcomes

for Drug Susceptible Tuberculosis

Efficacy Outcomes
Overall Effectiveness
+75%
Common Side Effects
Hepatotoxicity (clinical hepatitis)
+10%
Peripheral neuropathy
+20%
GI upset
+5%
Rash
+3%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov